At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GH Guardant Health Inc.
Pre-Mkt 10-06 05:05:03 EDT
187.22
+9.42
+5.30%
盘前187.00
-0.22-0.12%
04:51 EDT
High187.69Low176.37Vol1.75M
Open177.45D1 Closing177.80Amplitude6.37%
Mkt Cap25.12BTradable Cap24.30BTotal Shares134.20M
T/O322.72MT/O Rate1.35%Tradable Shares129.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Guardant Health Inc. Rises 5.07% in Regular Trading, UBS Report Highlights Liquid Biopsy Tailwinds
Market Focus  ·  03:03
Movement Alert｜Guardant Health Inc. Rises 5.07% in Regular Trading, UBS Report Highlights Liquid Biopsy Tailwinds
Guardant Health reports COSMOS study published in Cancer Research Communications
TIPRANKS  ·  10-05 23:30
Guardant Health reports COSMOS study published in Cancer Research Communications
Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences
Reuters  ·  10-05 23:27
Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
GlobeNewswire  ·  10-05 20:00
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Guardant Health price target raised to $200 from $190 at Guggenheim
TIPRANKS  ·  10-01
Guardant Health price target raised to $200 from $190 at Guggenheim
S&P 500 Futures Drop in Premarket Trading; Moog, AngloGold Ashanti Lag
Dow Jones  ·  09-28
S&P 500 Futures Drop in Premarket Trading; Moog, AngloGold Ashanti Lag
Guardant Health (GH) Receives a Buy from Bernstein
TIPRANKS  ·  09-26
Guardant Health (GH) Receives a Buy from Bernstein
FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.
Dow Jones  ·  09-24
FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.
Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300
Reuters  ·  09-18
Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300
US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee
Reuters  ·  09-17
US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee
Guardant Health on Track for Record High Close
Dow Jones  ·  09-17
Guardant Health on Track for Record High Close
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
MT Newswires Live  ·  09-16
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
Movement Alert｜Guardant Health Inc. Rises 5.31% in Regular Trading, Shield Blood Test Secures Major New Insurance Coverage Agreement
Market Focus  ·  09-16
Movement Alert｜Guardant Health Inc. Rises 5.31% in Regular Trading, Shield Blood Test Secures Major New Insurance Coverage Agreement
Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20
Reuters  ·  09-15
Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20
Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027
THOMSON REUTERS  ·  09-15
Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027
UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating
MT Newswires Live  ·  09-09
UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)
TIPRANKS  ·  09-08
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)
Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co
Dow Jones  ·  09-08
Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co
Guardant Health's Breast Cancer Diagnostic Approved by US FDA
MT Newswires Live  ·  09-08
Guardant Health's Breast Cancer Diagnostic Approved by US FDA
Rothschild & Co Redburn Initiates Guardant Health at Buy
MT Newswires Live  ·  09-08
Rothschild & Co Redburn Initiates Guardant Health at Buy

Introduction

Company Name.
Guardant Health Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Issue price:
--